NCT06379165View on ClinicalTrials.gov

Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain

PHASE3CompletedINTERVENTIONAL

Enrollment

192

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

July 11, 2023

Study Completion Date

July 13, 2023

Conditions

Pain

Interventions

DRUG

Meloxicam Nanocrystal Injection

30 mg (1 mL), once daily, by intravenous infusion

DRUG

Placebo

1 mL Placebo, once daily, by intravenous infusion

Trial Locations (1)

Unknown

Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06379165 - Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain | Biotech Hunter | Biotech Hunter